T1	Participants 45 120	for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
T2	Participants 269 325	patients with EGFR mutation-positive lung adenocarcinoma
T3	Participants 411 565	Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364).
T4	Participants 921 931	population
T5	Participants 1163 1175	345 patients
T6	Participants 2258 2276	patients with EGFR
T7	Participants 2753 2779	229 patients in LUX-Lung 3
T8	Participants 2796 2820	239 patients in LUX-Lung
T9	Participants 3459 3494	patients with del19 EGFR mutations.
T10	Participants 3523 3561	patients with Leu858Arg EGFR mutations
